Analysis of Sonazoid contrast-enhanced ultrasound for predicting the risk of microvascular invasion in hepatocellular carcinoma: a prospective multicenter study
Jundong Yao,Kaiyan Li,Hong Yang,Shichun Lu,Hong Ding,Yan Luo,Kai Li,Xiaoyan Xie,Wei Wu,Xiang Jing,Fangyi Liu,Jie Yu,Zhigang Cheng,Shuilian Tan,Jianping Dou,XueJuan Dong,Shuo Wang,Yiqiong Zhang,Yunlin Li,Erpeng Qi,Zhiyu Han,Ping Liang,XiaoLing Yu
DOI: https://doi.org/10.1007/s00330-023-09656-3
IF: 7.034
2023-04-28
European Radiology
Abstract:ObjectivesThe aim of this study was to evaluate the potential of Sonazoid contrast-enhanced ultrasound (SNZ-CEUS) as an imaging biomarker for preoperative prediction of microvascular invasion (MVI) in hepatocellular carcinoma (HCC).MethodsFrom August 2020 to March 2021, we conducted a prospective multicenter study on the clinical application of Sonazoid in liver tumor; a MVI prediction model was developed and validated by integrating clinical and imaging variables. Multivariate logistic regression analysis was used to establish the MVI prediction model; three models were developed: a clinical model, a SNZ-CEUS model, and a combined model and conduct external validation. We conducted subgroup analysis to investigate the performance of the SNZ-CEUS model in non-invasive prediction of MVI.ResultsOverall, 211 patients were evaluated. All patients were split into derivation (n = 170) and external validation (n = 41) cohorts. Patients who had MVI accounted for 89 of 211 (42.2%) patients. Multivariate analysis revealed that tumor size (> 49.2 mm), pathology differentiation, arterial phase heterogeneous enhancement pattern, non-single nodular gross morphology, washout time (< 90 s), and gray value ratio (≤ 0.50) were significantly associated with MVI. Combining these factors, the area under the receiver operating characteristic (AUROC) of the combined model in the derivation and external validation cohorts was 0.859 (95% confidence interval (CI): 0.803–0.914) and 0.812 (95% CI: 0.691–0.915), respectively. In subgroup analysis, the AUROC of the SNZ-CEUS model in diameter ≤ 30 mm and ˃ 30 mm cohorts were 0.819 (95% CI: 0.698–0.941) and 0.747 (95% CI: 0.670–0.824).ConclusionsOur model predicted the risk of MVI in HCC patients with high accuracy preoperatively.Clinical relevance statementSonazoid, a novel second-generation ultrasound contrast agent, can accumulate in the endothelial network and form a unique Kupffer phase in liver imaging. The preoperative non-invasive prediction model based on Sonazoid for MVI is helpful for clinicians to make individualized treatment decisions.Key Points• This is the first prospective multicenter study to analyze the possibility of SNZ-CEUS preoperatively predicting MVI.• The model established by combining SNZ-CEUS image features and clinical features has high predictive performance in both derivation cohort and external validation cohort.• The findings can help clinicians predict MVI in HCC patients before surgery and provide a basis for optimizing surgical management and monitoring strategies for HCC patients.
radiology, nuclear medicine & medical imaging